June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an additional five years, to further advance findings in human genomics research in cardiovascular diseases. The expanded agreement will focus on joint precision cardiology target identification, leveraging the established human cardiomyocyte platform to rapidly validate observations, and discovery of novel therapeutic approaches.
Current efforts are directed to develop potential treatment options for patients with specific forms of cardiovascular disease such as dilated cardiomyopathy (DCM), among others. DCM is a type of heart disease characterized by the enlargement of the heart's chambers, which leads to a decreased ability to pump blood effectively. This condition can result in heart failure and other complications if left untreated.
Established in 2013, this longstanding collaboration combines the Broad Institute’s extensive expertise in genomics and biology with Bayer’s in-depth experience in small, chemically manufactured molecules and biologics drug discovery to advance drug discovery research for novel cardiovascular therapeutics. This strategic research alliance already has resulted in a number of joint publications and conference presentations, and it has paved the way for Bayer's announcement in May 2025 regarding the initiation of a Phase I study with its investigational highly selective G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor which has a potential to help control the electrical activity of heart cells in patients with atrial fibrillation (AFib).
“We are constantly evaluating novel approaches to treat cardiovascular diseases that affect millions of people worldwide. Our shared commitment is to explore novel therapeutic targets and modalities in various cardiovascular and renal diseases to help deliver new treatment options to patients in need,” said Andrea Haegebarth, Ph.D., Global Head of Research and Early Development for Cardiovascular, Renal, and Immunology at Bayer’s Pharmaceuticals Division. “The first joint therapeutic project entered the clinic last month and we are excited to collaborate further with the esteemed scientists at the Broad Institute to identify and develop disease-modifying therapeutics treating underlying causes of cardiovascular diseases.”
“I am delighted to see Broad and Bayer continue this fruitful collaboration in cardiovascular research,” said Todd Golub, director and founding core member of the Broad Institute. “By working together, Broad and Bayer are able to make advances that neither organization could make on its own.”
Academic collaborations are integral to Bayer's research and development strategy, aimed at delivering innovative treatment solutions to patients, particularly in areas with significant unmet medical needs, such as cardiovascular health. Bayer’s strategic focus in cardiovascular research emphasizes precision drug development, facilitating the rapid identification of the most promising targets and commercially viable programs.
Bayer with its Bayer Research & Innovation Center (BRIC) is closely located to the Broad Institute in Kendall Square, Cambridge, MA. BRIC houses a center of precision oncology research as well as an experienced team of scientists focused on research and early development for developing precision cardiovascular, renal, and immunology therapeutics. BRIC is also home to Bayer Co.Lab Cambridge which is part of a pioneering global network of life science incubators focused on disruptive innovation and scientific breakthroughs.
Financial details have not been disclosed.
1. Ferreira A, Ferreira V, Antunes MM, Lousinha A, Pereira-da-Silva T, Antunes D, Cunha PS, Oliveira M, Ferreira RC, Rosa SA. Dilated Cardiomyopathy: A Comprehensive Approach to Diagnosis and Risk Stratification. Biomedicines. 2023 Mar 9;11(3):834. doi: 10.3390/biomedicines11030834. PMID: 36979813; PMCID: PMC10044994.
May 27, 2025 
